Skip to main content
Top
Published in: Hepatology International 2/2010

01-06-2010 | Original Article

Longitudinal assessment of prognostic factors for patients with hepatorenal syndrome in a tertiary center

Authors: Ya-Wen Yang, Che-Hsiung Wu, Rey-Heng Hu, Ming-Chin Ho, Meng-Kun Tsai, Yao-Ming Wu, Po-Huang Lee

Published in: Hepatology International | Issue 2/2010

Login to get access

Abstract

Introduction

Hepatorenal syndrome (HRS) is one of the serious complications in patients with advanced cirrhosis and ascites. In tertiary centers, most patients were classified as having type 1 HRS for their rapid progressive diseases. However, no significant predictors have been assessed previously for patients with type 1 HRS. In addition to the initial model of end-stage liver disease (MELD) scores and biochemistry parameters, we want to further investigate the prognostic importance of changes in MELD scores and biochemistry parameters over time for patients with type 1 HRS.

Materials and methods

Data from type 1 HRS patients were incorporated, including their demographic, clinical progression, all recording biochemical parameters, therapeutic methods, and outcomes.

Results

A total of 103 patients were included in our study. According to the definition of the International Ascites Club, 67 patients (or 65%) had type 1 HRS whereas 36 (or 35%) had type 2 HRS. According to the multivariate COX proportional hazards regression model, either initial biochemistry parameters or MELD scores were not significantly associated with prognosis. By time-dependent proportional hazards model, each point elevated in creatinine (CRE) and total bilirubin (TBI) levels during the admission increased mortality risk by 29 and 4%, respectively. Increasing albumin level during the admission showed its protective value. Changes in MELD score simple during the admission, which were calculated by CRE and TBI [3.8 × log (bilirubin (mg/dl)] + 9.6 × log [Creatinine (mg/dl) + 6.43], were significant predictor for patients with type 1 HRS.

Conclusion

In patients with type 1 HRS, changes in TBI, CRE, and albumin level during the admission were associated with prognosis. Changes in MELD score simple is superior to initial and changes in MELD scores to predict prognosis in patients with type 1 HRS.
Literature
2.
go back to reference Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38(Suppl 1):S69–S89CrossRefPubMed Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38(Suppl 1):S69–S89CrossRefPubMed
3.
go back to reference Grange JD, Amiot X. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterol Clin Biol 2000;24:378–379PubMed Grange JD, Amiot X. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterol Clin Biol 2000;24:378–379PubMed
4.
go back to reference Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004;40:897–903CrossRefPubMed Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004;40:897–903CrossRefPubMed
5.
go back to reference Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2004;41:1282–1289CrossRef Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2004;41:1282–1289CrossRef
6.
go back to reference Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int 2006;26:834–839CrossRefPubMed Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int 2006;26:834–839CrossRefPubMed
7.
go back to reference Bambha K, Kim WR, Kremers WK, Therneau TM, Kamath PS, Wiesner R, et al. Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant 2004;4(11):1798–804CrossRefPubMed Bambha K, Kim WR, Kremers WK, Therneau TM, Kamath PS, Wiesner R, et al. Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant 2004;4(11):1798–804CrossRefPubMed
8.
go back to reference Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Lee PC, et al. Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 2005;42:826–832CrossRefPubMed Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Lee PC, et al. Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 2005;42:826–832CrossRefPubMed
9.
go back to reference Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transplant 2003;9:12–18CrossRef Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transplant 2003;9:12–18CrossRef
10.
go back to reference Mitzner S, Klammt S, Stange J, Schmidt R. Albumin regeneration in liver support-comparison of different methods. Ther Apher Dial 2006;10(2):108–117CrossRefPubMed Mitzner S, Klammt S, Stange J, Schmidt R. Albumin regeneration in liver support-comparison of different methods. Ther Apher Dial 2006;10(2):108–117CrossRefPubMed
11.
go back to reference Sundaram V, Al-Osaimi AM, Lewis JJ, Lisman T, Caldwell SH. Severe prolongation of the INR in spur cell anemia of cirrhosis: true-true and related? Dig Dis Sci 2006;51(7):1203–1205CrossRefPubMed Sundaram V, Al-Osaimi AM, Lewis JJ, Lisman T, Caldwell SH. Severe prolongation of the INR in spur cell anemia of cirrhosis: true-true and related? Dig Dis Sci 2006;51(7):1203–1205CrossRefPubMed
12.
go back to reference Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 2006;21(2):478–482CrossRefPubMed Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 2006;21(2):478–482CrossRefPubMed
Metadata
Title
Longitudinal assessment of prognostic factors for patients with hepatorenal syndrome in a tertiary center
Authors
Ya-Wen Yang
Che-Hsiung Wu
Rey-Heng Hu
Ming-Chin Ho
Meng-Kun Tsai
Yao-Ming Wu
Po-Huang Lee
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 2/2010
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-010-9180-8

Other articles of this Issue 2/2010

Hepatology International 2/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.